Higround and Minecraft Join Forces to Showcase Gaming as an Art Form
22.5.2024 19:00:00 EEST | Business Wire | Press release
Higround, a leading provider of premium gaming peripherals collaborates with Minecraft, the beloved sandbox game, to unveil an exclusive collection celebrating gaming as an art form. The collaboration brings to life the art and creativity of Minecraft players, inviting gamers to explore and express themselves through a range of meticulously crafted peripherals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240522106753/en/
The Higround x Minecraft collection features two Summit 2.0 65 keyboards. (Photo: Business Wire)
The Higround x Minecraft collaboration is a testament to the use of gaming as a creative medium and art form. The collection features a lineup of Basecamp 65, Summit 65, and Performance 65 keyboards, alongside matching mousepads and other accessories. Each product showcases iconic artwork from the blocky worlds of Minecraft, capturing the essence of its diverse landscapes, characters, and creatures.
From lush forests to deep mines, this collection invites gamers to bring to life the artistry they create within their individual worlds.
“Most of society views video games as a juvenile pastime. Yet, we believe video games, especially ones like Minecraft, are an art form,” says Creative Director and co-Founder of Higround, Rustin Sotoodeh. “Minecraft's gameplay spawned a generation of creatives who, for the first time, were able to architect houses or design clothes at an early age. Our collaboration with Minecraft shows the world that side of games—the creative side.”
The Higround x Minecraft collection will be available for purchase on May 29 at 12 PM PT, providing gamers with the opportunity to bring the iconic artwork of Minecraft into their gaming spaces. For more information and updates on the release, visit Higround.co.
ABOUT HIGROUND
Higround is a lifestyle and computer peripheral brand that seeks to embody elevated gaming culture. Founded by Rustin Sotoodeh and Kha Lu, Higround creates high-quality peripherals with unique designs that fuse fashion, gaming, and technology. Each capsule features a distinctive array of items known to sell out rapidly. The brand has garnered acclaim for collaborations with renowned brands such as Naruto, SEGA, and Brain Dead. In 2021, the brand was acquired by esports powerhouse 100 Thieves.
ABOUT MINECRAFT
Minecraft is the best-selling video game of all time with millions of players in every country and territory around the world including Antarctica and the Vatican City. At its core, Minecraft is a game about placing blocks and going on adventures. The Minecraft franchise continues to reach new players through ongoing game updates, games like Minecraft Education, Minecraft Legends, and Minecraft Dungeons, a diverse line of consumer products, a growing library of in-game Marketplace content, books and an upcoming major motion picture.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522106753/en/
Contact information
For more information, please contact:
Kelly Kim, kkim@higround.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom